Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07204275 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)

Study acronym: OLYMPUS
StatusRecruiting
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study sites: 114 to 115
  2. Trial sites expanded: 111 → 114 locationsv20
  3. Trial sites expanded: 108 → 111 locationsv19
  4. Trial sites expanded: 102 → 108 locationsv18
  5. Trial sites expanded: 98 → 102 locationsv17
  6. Trial sites expanded: 93 → 98 locationsv16
  7. Trial sites expanded: 86 → 93 locationsv15
  8. Trial sites expanded: 79 → 86 locationsv14
  9. Trial sites expanded: 73 → 79 locations Secondary endpoints: 2 to 3 · Study title shortened, about 2 wordsv13 Show 2 more changesShow less
    • Secondary endpoints: 2 to 3
    • Study title shortened, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  10. Trial sites expanded: 69 → 73 locationsv12
  11. Study sites: 63 to 69v11
  12. Study sites: 51 to 63v10
  13. Study sites: 38 to 51 Collaborators expanded, about 8 wordsv9 Show 1 more changeShow less
    • Collaborators expanded, about 8 words

    See this version in full on ClinicalTrials.gov ↗

  14. Study sites: 29 to 38v8
  15. Study sites: 25 to 29v7
  16. Study sites: 21 to 25v6
  17. Study sites: 14 to 21v5
  18. Study sites: 8 to 14v4
  19. Study sites: 4 to 8v3
  20. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 4 · Start date changed from estimate of Oct 6, 2025 to Sep 30, 2025v2 Show 2 more changesShow less
    • Study sites: 0 to 4
    • Start date changed from estimate of Oct 6, 2025 to Sep 30, 2025
  21. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the efficacy, safety, and tolerability of povetacicept in participants with primary membranous nephropathy (pMN).
Trial Details
NCT Number NCT07204275
Lead Sponsor Vertex Pharmaceuticals Incorporated
Collaborators: Zai Lab (Shanghai) Co., Ltd. (for China only)
Conditions Primary Membranous Nephropathy
Enrollment 176 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov